REIMAGING PHARMACEUTICAL INNOVATION.

Slides:



Advertisements
Similar presentations
THE CHALLENGES & OPORTUNITIES OF ACCESS TO MEDICINES IN AFRICA Dr Pascoal MOCUMBI, orig Mozambique,High Representative EDCTP ABRASCO/WFPHA.
Advertisements

R&D Financing by the Bill & Melinda Gates Foundation
1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.
TM OBTransformation.com. C-Level Trends of Note ISSUES OF NOTE Funding New Business Entering New Markets Globalization REQUIRES Innovation Flexibility.
Consultative expert working group - proposals Barcelona
Jean O. Lanjouw February, 2003 The Global Patent System and the Availability of Pharmaceuticals in Poor Countries.
The Medical Innovation Prize Fund S.2210, 110 th U.S. Congress David Reynolds, DrPH Senior Health Policy Advisor Senator Bernie Sanders
Pre Tender Meeting UNICEF Supply Division, December 2008 Rob Matthews UNICEF Vaccine Procurement for Developing Countries.
Australia’s new development policy and performance framework.
Global Health Program Guiding Principles April 2002.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
(see also Chapter 13).  Sustainability is being able to endure and survive in an environment into the future.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
EUROPEAN NETWORK FOR GLOBAL HEALTH TO EUROPEAN ALLIANCE AGAINST MALARIA Barcelona, 28 de febrero de 2007.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
Session 8. The volatility of private capital flows in developing countries and the potential role of BRICS development bank to counter pro-cyclicality.
Introduction to. Sep. 4, 1997 r Engineering economy relates or applies many concepts from economics, mathematics, finance, accounting, statistics, and.
Lecture 15 October 25, 2012 Solutions to Poverty & Excessive Inequality.
Stakeholder Objectives
How to determine medicines benefits policy and program needs?
UK Policy considerations on increasing access to medicines for the poor in developing countries. DEPARTMENT FOR INTERNATIONAL DEVELOPMENT.
Marketing Dynamics Lecture 1 Jeanette MacNaught. Session objectives Definition of marketing The development of marketing as a way of doing business Marketing.
Slide 1.1 Principles of Marketing Marketing Now Marketing now Chapter 1.
The Challenges of Managing Microinsurance Schemes in Uganda Objective to analyze the challenges of managing micro- insurance schemes in Uganda. (i) Introduction.
Summary from the Economics Track With thanks to all track participants, presenters, rapporteurs, moderators and organizers.
A new start for the Lisbon Strategy Knowledge and innovation for growth.
Pharmaceutical system strengthening – Is there a need for a new paradigm? Andreas Seiter The World Bank ICIUM 2011, Antalya 1.
Health challenges in an enlarged Europe Report from Parallel Session A1 Dr. Natasha Azzopardi Muscat Ministry of Health - Malta.
1 Domestic Financing for Health Parliamentarian Round Table March 2014,Joburg, SA Linda Mafu, Head Political Advocacy and Civil Society Department,
World Health Organization "3 by 5" Target Treat 3 million by 2005.
Business models Halme - 03/12/20151 BUSINESS MODELS FOR MATERIAL EFFICIENCY SERVICES: CONCEPTUALIZATION AND APPLICATION Minna Halme, Markku Anttonen, Mika.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
Patents, Prizes, AMCs and CAMCs Aidan Hollis University of Calgary October 2007.
Distribution of income. Direct and Indirect Taxation Direct taxes are paid directly to the tax authority by the taxpayer: –Personal income taxes: on all.
Efficiency, Effectiveness, and Financial Sustainability: The Importance of Country Ownership Dr Bernhard Schwartländer UNAIDS.
The Role of New Markets Advisors in Healthcare Case Study in Health Insurance Innovation.
HEALTH CHARTER Presentation to the Portfolio Committee August 2005.
2nd African Decent Work Symposium: Yaoundé, Cameroon, 6-8 October THE SOCIAL SECURITY EXTENSION CHALLENGE: INCOME SECURITY AND HEALTH BENEFITS. Dr.
Role of innovation in state of the art healthcare delivery in Russia 27 October 2015, USRBC Annual Meeting.
©2015 Cengage Learning. All Rights Reserved. May not be scanned, copied or duplicated, or posted to a publicly accessible website, in whole or in part.
Poverty & Excessive Inequality
Unit 5 - Personal Finance #
Economic Considerations
Operational Objectives
The first fuel to combat climate change. Energy efficiency www
Measuring Impact Guide
HEALTH ECONOMICS BASICS
REPURPOSING - SOCIAL IMPACT BONDS FOR MEDICINE
Debt relief.
Tax Reform Session 5-6.
Economic Considerations
Evaluating Job Offers: A Journey in Comparisons
Quality of government expenditure
Chapter 18 Asset Allocation
Results Oriented Program Formulation
Next topic: Policies for Growth and Development
Next topic: Policies for Growth and Development
© 2001 South-Western, a division of Thomson Learning
An Industry Perspective Nicole Denjoy COCIR Secretary General
22nd International AIDS Conference Amsterdam, 24 July 2018
ENTREPRENEURIAL FINANCE Fifth Edition
Fifth Annual Pharmaceutical Regulation & Compliance Congress
Access to Medicines: NCDs & NTDS: INSULIN VS PRAZIQUANTEL
Globalization.
Fiscal Policy: Spending & Taxing
Programme Management Board
Chapter 1 Characteristics of Business
Access to Essential Medicines
Presentation to AES (Agricultural Economics Society),
Tracie Wills Senior Commissioning Officer
Presentation transcript:

REIMAGING PHARMACEUTICAL INNOVATION. by:- Balaji Kumar Panigrahi

Health Impact Fund (HIF) A new way of stimulating Pharmaceutical Innovation HIF

INTRODUCTION Making new medicines accessible The Health Impact Fund (HIF) is a proposed new way of paying for pharmaceutical innovation. The HIF would incentivize the development and delivery of new medicines by paying for performance All pharmaceutical firms worldwide would have the option of registering new medicines with the HIF By registering, a firm would agree to provide its drug at cost anywhere it is needed, and in exchange for foregoing the normal profits from drug sales, the firm would be rewarded based on the HIF's assessment of the actual global health impact of the drug

How would you organise the Pharmaceutical Industry ? The main principle Real-time open Access to the world of all important medicine regardless of their income. R&D investment target the innovations that promise the large health gains. The entire system is cost-effective so that money spend on the medicine achieve as much as possible for human health.

The existing system Focused innovation is distorted by huge economic inequalities, which sustain the “10/90 gap”, and by excessive rewards for “me-too” and maintenance drugs.

Overall efficiency & Wasteful Marketing. Overall efficiency is greatly diminished by lobbing,gamming,patenting and litigation, by dead weight losses, and by incentives for wasteful marketing. How it can Controlled:- Regular surveillance using IT in the field of Pharmaceutical.

Moral pressure on innovation isn’t the solution Like individuals, pharmaceutical firms have duties of rescues: to deliver important drug cheaply to poor patients and to developing new medicine for the disease for the poor. Driven out of the market.

The potential gains are enormous In less developing countries some 50,000 premature death daily that is 1/3 of all human death are due to disease of poverty such as TB,diarrhea,Respiratory infection, malaria and conditions, measles and other child hood diseases,hepatites and sexually transmitted diseases.

How can we change the system?

Health Impact Fund Works Reward Mechanism HIF would offer a fixed reward pool each year $ 6 billion say, financed through taxes and /or endowment income. Rewarded for 10 years. Product’s rewarded share in year X would equal its share of total health impact of all registered products in year x After 10 years every years the product should be re-evaluated annually on the basis of new data and innovator will paid for it.

Health impact fund benefits all parties. For innovators Creates a new market of patient who cannot pay high price Provide additional profitable research opportunity Bring relief from moral pressure to accept losses for the sake of protecting the health of poorer patients

Health impact fund benefits all parties. For Patients Increase the likelihood that best medicine is available Ensure that important available medicines are affordable and supported

Health impact fund benefits all parties. For Funding governments /taxpayers Make spreading on medicines vastly more efficiency. Greatly reduces the human and economic burdens of disease.

Conclusion If this type of Health Impact funding system is developed, the innovators will be inspired for the new research & development and patients will get affordable medicines and the innovators should also be rewarded for it. From this ,the wastage of money in the research will be controlled and it will help the country to maintain the health care system and economic condition will be stabilize.

Thank u 